Option chain shows key data for Cullinan Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cullinan Therapeutics.

Cullinan Therapeutics (NASDAQ:CGEM) Stock, Option Chain

Cullinan Therapeutics

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Amgen stock

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

General

AMGN

CGEM

REGN

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent dosing benefits.

Amgen&#39;s Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

Headquarters_Rahway-Site-Entrance_HI

Trading Ideas

Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck&#39;s pipeline for treating B-cell malignancies and autoimmune diseases. The deal, valued at up to $1.3 billion, is expected to close in Q3 2024.

Merck&#39;s $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan&#39;s Investigational Drug, Says Analyst

Intraday Update

Markets

Movers

ADXN

ALTM

ANVS

APLD

ATXI

CALT

CAUD

CJJD

CLVR

CSSE

CVEO

CYCC

DAVE

DCPH

ENLV

FLGC

FTEL

FULT

HOPE

HTLF

IBRX

INHD

IONM

ISUN

KYTX

MESO

MPLN

MULN

NUZE

NWGL

OCGN

PAHC

PRME

SLNO

SOFI

SSKN

TCJH

TSLA

ZVSA

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics Inc

Capgemini SE

Rocket Lab USA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NYSE">RKLB</a>) short percent of float has fallen 5.13% since its last report. The company recently reported that it has 58.95 million shares sold short, which is 16.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Rocket Lab USA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732210217_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Rocket Lab USA has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Rocket Lab USA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Rocket Lab USA's peer group average for short interest as a percentage of float is 2.32%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

RKLB

Peering Into Rocket Lab USA's Recent Short Interest

Dollar Tree's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NYSE">DLTR</a>) short percent of float has risen 5.59% since its last report. The company recently reported that it has 12.05 million shares sold short, which is 6.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dollar Tree Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732210212_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dollar Tree has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Dollar Tree's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dollar Tree's peer group average for short interest as a percentage of float is 3.08%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

DLTR

Peering Into Dollar Tree's Recent Short Interest

Wells Fargo analyst Zachary Fadem maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Equal-Weight and raises the price target from $140 to $165.

Price Target

Wells Fargo Maintains Equal-Weight on Williams-Sonoma, Raises Price Target to $165

<a href="https://x.com/mattgaetz/status/1859649045553402285">https://x.com/mattgaetz/status/1859649045553402285</a>
I had excellent meetings with Senators yesterday. I appreciate their thoughtful feedback - and the incredible support of so many. While the momentum was strong, it is clear that my confirmation was unfairly becoming a distraction to the critical work of the Trump/Vance Transition. There is no time to waste on a needlessly protracted Washington scuffle, thus I'll be withdrawing my name from consideration to serve as Attorney General. Trump's DOJ must be in place and ready on Day 1. I remain fully committed to see that Donald J. Trump is the most successful President in history. I will forever be honored that President Trump nominated me to lead the Department of Justice and I'm certain he will Save America.

Macro Economic Events

Politics

Economics

MSOS

Matt Gaetz Posts On X ".., It Is Clear That My Confirmation Was Unfairly Becoming A Distraction To The Critical Work Of The Trump/Vance Transition.  There Is No Time To Waste On A Needlessly Protracted Washington Scuffle, Thus I'll Be Withdrawing My Name From Consideration To Serve As Attorney General.  Trump's DOJ Must Be In Place And Ready On Day 1"

Truist Securities analyst William Stein maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $167 to $169.

NVDA

Truist Securities Maintains Buy on NVIDIA, Raises Price Target to $169

Shares of Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) plunged more than 6% during Thursday morning trading in New York, marking their steepest <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">decline since January 2024. </a>
The drop has wiped out over $120 billion in market capitalization, dragging Alphabet's valuation below the critical $2 trillion threshold.
<h3 class="wp-block-heading">Chart: Alphabet Suffers Worst Day Since Late January 2023</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21120531/image-223-1024x501.png" alt="" class="wp-image-659358" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21120531/image-223-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21120531/image-223-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21120531/image-223-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21120531/image-223-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21120531/image-223.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Why The Selloff? </h3>
The sharp decline follows the U.S. Department of Justice's (DOJ) announcement of sweeping remedies in its high-profile antitrust lawsuit against Google. 
On Wednesday, the DOJ proposed measures aimed at curbing Google's dominance in search and digital advertising, potentially reshaping <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">Alphabet&#8217;s core business operations.</a>
The most aggressive recommendation is a requirement for Alphabet to divest Google Chrome, the internet's leading browser with over 60% market share globally. 
Regulators view Chrome as a cornerstone of Alphabet's ability to consolidate its dominance in both search and ad tech markets. This divestiture would mark an unprecedented government intervention into one of the tech giant&#8217;s most integrated and profitable ecosystems.
Other proposals include forcing Google to share search data with competitors, thus leveling the playing field for rival search engines, and to end default search agreements, which make Google the automatic search engine on devices and web browsers like Apple's Safari.
"Google's unlawful behavior has deprived rivals not only of critical distribution channels but also distribution partners who could otherwise enable entry into these markets by competitors in new and innovative ways," the DOJ&nbsp;said in a statement.
<h3 class="wp-block-heading">What&#8217;s At Stake? </h3>
Alphabet&#8217;s business model relies heavily on the synergies between its services. In the third quarter of 2024, Alphabet&#8217;s &#8220;Search &amp; Other&#8221; segment generated $49.4 billion, accounting for 56% of the company's total revenue for the quarter.
For the full fiscal year 2023, Alphabet reported $307.4 billion in total revenue. The revenue breakdown highlights the scale of Alphabet&#8217;s reliance on search and ad-driven income:
<ul>
<li>Google Search &amp; Other: $175.0 billion</li>
<li>YouTube Ads: $31.5 billion</li>
<li>Google Network: $31.3 billion</li>
<li>Google Cloud: $33.1 billion</li>
<li>Other Revenues: $34.7 billion</li>
<li>Other Bets: $1.5 billion</li>
</ul>
These numbers underline the DOJ's focus on Alphabet's most lucrative business segments. A forced breakup of Chrome, combined with mandated data-sharing and restrictions on default agreements may threaten to erode Alphabet&#8217;s competitive edge and profitability.
<h3 class="wp-block-heading">Expert Take: Google's Strategic Challenges</h3>
Ahead of the DOJ announcement, RBC Capital Markets shared insights from a conversation with Brian O&#8217;Kelley, CEO &amp; co-founder of Scope3 and a seasoned expert in ad tech. O&#8217;Kelley raised critical points about Alphabet&#8217;s future in light of the antitrust case:
<ol>
<li>Open Internet vs. AI: O&#8217;Kelley sees the value of open internet a declining asset since consumers shift toward AI-powered experiences. According to him, &#8220;the DOJ is litigating against the last decade, as opposed to current day looking forward.&#8221;</li>
<li>Chrome's Role: He indicates that Google&#8217;s network business &#8220;isn&#8217;t depending on owning the legacy ad tech assets.&#8221; Even without Chrome, users will continue going to Google.com for search, suggesting that Chrome&#8217;s value may be less critical than it seems.</li>
<li>Regulatory Differences: O&#8217;Kelley highlights stark contrasts in regulatory approaches between Europe and the U.S. While Europe is moving swiftly to ban cookies and enforce stricter privacy rules, U.S. regulation may take longer to materialize, giving Alphabet more time to adapt.</li>
</ol>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42116183/michael-saylor-predicted-bitcoin-to-hit-13-million-if-it-happens-it-will-entail-massive-hyperinflation-analyst-warns">Michael Saylor Predicted Bitcoin To Hit $13 Million — If It Happens, It Will Entail &#8216;Massive Hyperinflation,&#8217; Analyst Warns</a></li>
</ul>
Image: Shutterstock

Equities

Government

Regulations

Legal

Tech

GOOG

GOOGL

Alphabet Bleeds Over $120 Billion In Market Value, Eyes Worst Day In 10 Months After DOJ Demands Google Chrome Sale

Wedbush analyst Seth Basham maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Neutral and raises the price target from $135 to $175.

Wedbush Maintains Neutral on Williams-Sonoma, Raises Price Target to $175

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) has caught traders&#8217; attention thanks to bullish chart patterns, even though price remains flat <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">for the time being</a>.
What Happened: After a 177% surge in the last month, crypto trader DonAlt highlighted Dogecoin's impressive chart, suggesting that the meme coin is poised for further gains.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> Actually kinda looks good A dog kind of deserves at least 2 legs no? <a href="https://t.co/Lia596NXFl">pic.twitter.com/Lia596NXFl</a>
&mdash; DonAlt (@CryptoDonAlt) <a href="https://twitter.com/CryptoDonAlt/status/1858791067488788856?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
More Crypto Online <a href="https://x.com/Morecryptoonl/status/1859255908011798821">points</a> out that Dogecoin&#8217;s support lies between $0.25 and $0.34, and after a 3.7% dip over the last week, the correction is almost complete. 
However, the trader anticipates a potential continuation before a breakout above $0.445, which could propel prices to $0.60.
Trader Koala <a href="https://x.com/trader_koala/status/1859382420933579078">takes</a> a cautious yet optimistic stance, calling Dogecoin's chart the "best-looking" and suggesting any pullbacks should be viewed as buying opportunities. 
He sees the only tailwind risk is the elimination of &#8220;Department of Government Efficiency.&#8221;
Crypto analyst Kevin <a href="https://x.com/Kev_Capital_TA/status/1859632545379295449">predicts</a> that the longer the consolidation, the bigger the next leg up, potentially marking the start of Dogecoin&#8217;s largest bull run yet.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42060120/dogecoin-up-6-after-elon-musks-dogefather-tweet-is-this-the-start-of-a-parabolic-run">Dogecoin Up 6% After Elon Musk&#8217;s &#8216;Dogefather&#8217; Tweet: Is This The Start Of A &#8216;Parabolic Run&#8217;?</a>
Why It Matters: Ali Martinez, a crypto chart analyst, <a href="https://x.com/ali_charts/status/1859560640869806344">revealed</a> that Dogecoin whales have bought over 550 million DOGE, worth $214.5 million, in the past week.
IntoTheBlock data shows large transaction volume and daily active addresses increased 41.1% and 34.9%, respectively, in a single day. 
Coinglass data shows long liquidations at the lowest level ($7.4 million) since Nov. 9, while open interest remains high, exceeding $3.07 billion.
Price Action: At the time of writing, Dogecoin is trading at $0.3846, up 1.7% over the past 24 hours.
Read Next: &nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42048200/pepe-dogecoin-at-the-center-of-crypto-influencer-discussion-if-people-want-to-make-money-theyre-going-to-go-to-meme-coins">Pepe, Dogecoin At The Center Of Crypto Influencer Discussion: &#8216;If People Want To Make Money, They&#8217;re Going To Go To Meme Coins&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Dogecoin Up 177% Over The Past Month, But Traders Say It's Not Done Yet: 'A Dog Deserves At Least Two Legs,' Says One

Wedbush analyst Matt Bryson maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Outperform and raises the price target from $160 to $175.

Wedbush Maintains Outperform on NVIDIA, Raises Price Target to $175

Nano Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) shares are trading higher Thursday potentially following a corporate announcement regarding a key addition to the company&#8217;s leadership. Here&#8217;s <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41913106/whats-going-on-with-nano-nuclear-energy-stock-tuesday">what you need to know.</a>
What To Know: Nano Nuclear Energy announced that John Vonglis, former CFO of the U.S. Department of Energy, has taken an active corporate role at NANO Nuclear as executive director of Global Government Affairs. His responsibilities include managing relationships with government agencies and aligning the company's nuclear energy projects with public funding opportunities and policy initiatives.
Vonglis, who has extensive experience in energy financing and government programs, previously held roles as the acting director of the DOE&#8217;s Advanced Research Projects Agency-Energy (ARPA-E) and as chief risk officer of the DOE.
&#8220;His decision to step into an operational position is an important validation of our efforts to lead on the cutting edge of the U.S. nuclear energy industry,&#8221; said Jay Yu, founder and chairman of NANO Nuclear Energy. 
Regulatory headwinds are one of the biggest concerns for investors in the nuclear space. Vonglis is expected to play a vital role in strengthening relationships with key government agencies and policymakers. NANO Nuclear shares raced higher on the news.
NANO Nuclear Energy is focused on developing advanced nuclear microreactors for portable and on-demand clean energy solutions. Its main products, the &#8220;ZEUS&#8221; solid-core battery reactor and the &#8220;ODIN&#8221; low-pressure coolant reactor, are under development. 
The company is also working on creating infrastructure for High-Assay Low-Enriched Uranium (HALEU) fuel fabrication and transportation through its subsidiaries. Additionally, the company is exploring applications of nuclear technology in space through its space-focused division.
NNE Price Action: Nano Nuclear energy were up 25.1% at $28.95 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="552" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21104701/NNE-1024x552.png" alt="" class="wp-image-659125" style="width:463px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21104701/NNE-1024x552.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21104701/NNE-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21104701/NNE-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21104701/NNE.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42107863/us-futures-head-lower-as-nvidia-reports-slowdown-in-quarterly-revenue-growth-expert-says-market-weakness-is-perfectly-normal-but-late-november-is-still-possible">US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is &#8216;Perfectly Normal,&#8217; But Late November Rally Is Still Possible</a></li>
</ul>
Image Via Shutterstock.

Nano Nuclear Energy Shares Are On The Rise Today: What's Going On?

<a href="https://www.chicagofed.org/publications/speeches/2024/nov-21-central-indiana-corporate-partnership" title="https://www.chicagofed.org/publications/speeches/2024/nov-21-central-indiana-corporate-partnership">https://www.chicagofed.org/publications/speeches/2024/nov-21-central-indiana-corporate-partnership</a>

Federal Reserve

Fed's Goolsbee Says It May Make Sense To Slow Pace Of Interest Rate Cuts As U.s. Central Bank Gets Close To Where Rates Will Settle; Over The Next Year, It Feels Like Rates Will End Up A Fair Bit Lower Than Where They Are Today; Inflation Is On Its Way Down To 2%; Labor Market Is Close To Stable Full Employment

UBS analyst William Appicelli maintains Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) with a Buy and raises the price target from $75 to $80.

UBS Maintains Buy on Spire, Raises Price Target to $80

Wedbush analyst Daniel Ives maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Neutral and raises the price target from $130 to $160.

SNOW

Wedbush Maintains Neutral on Snowflake, Raises Price Target to $160

Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) has secured a new agreement with the U.S. Department of Agriculture (USDA), <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42113569/verizon-business-secures-new-5-year-agreement-with-the-u-s-department-of-agriculture-usda" rel="noreferrer noopener">valued at over $21 million for the first year.</a>
This contract will enhance the USDA&#8217;s connectivity across the country, supporting more than 60,000 lines of service.
Verizon will provide wireless services and service-enabled devices, with the potential for mobile broadband to be implemented on connected laptops across USDA&#8217;s field offices.
The partnership will play a pivotal role in the USDA&#8217;s mission, which focuses on modernizing agriculture and supporting rural development. By integrating advanced connectivity solutions, the USDA can improve its data management, streamline operations, and make informed decisions that impact agricultural productivity, food security, and rural communities.
The contract will also aid in disaster response and resource management, ensuring the USDA remains equipped with cutting-edge technology.
Also Read:<a target="_blank" href="https://www.benzinga.com/24/11/42112078/international-criminal-court-issues-arrest-warrants-for-netanyahu-gallant" rel="noreferrer noopener"> International Criminal Court Issues Arrest Warrants For Israeli Prime Minister Netanyahu, Gallant For War Crimes</a>
Michael Adams, Verizon&#8217;s Vice President for Federal Civilian Services, expressed pride in the partnership, emphasizing Verizon&#8217;s commitment to delivering innovative connectivity solutions.
&#8220;This contract not only reflects the USDA&#8217;s trust in Verizon&#8217;s capabilities but also highlights our shared commitment to leveraging technology in ways that directly support the agency&#8217;s critical mission,&#8221; Adams added.
Verizon Business, a provider of communications services to the U.S. federal government, continues to strengthen its role in supporting government agencies with advanced technology services.
This agreement underscores Verizon&#8217;s dedication to enabling the USDA to meet its critical mission while enhancing service delivery across the nation.
Price Action: VZ shares are trading higher by 0.47% to $42.42 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42107863/us-futures-head-lower-as-nvidia-reports-slowdown-in-quarterly-revenue-growth-expert-says-market-weakness-is-perfectly-normal-but-late-november-is-still-possible" target="_blank" rel="noreferrer noopener">US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is &#8216;Perfectly Normal,&#8217; But Late November Rally Is Still Possible</a></li>
</ul>

Contracts

Verizon Secures 5-Year Agreement With USDA To Enhance Connectivity and Support Rural Development

Live On CNBC, Brad Gerstner Announces Bought More Alphabet Inc. - Class A

Investors with a lot of money to spend have taken a bullish stance on XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with XPEV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for XPeng.
This isn't normal.
The overall sentiment of these big-money traders is split between 53% bullish and 40%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $931,729, and 7 are calls, for a total amount of $526,364.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $15.0 for XPeng over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for XPeng's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of XPeng's whale trades within a strike price range from $7.0 to $15.0 in the last 30 days. 
<h3>XPeng Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732209532_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$4.6</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$15.00</td>
<td>$225.0K</td>
<td align="right">62</td>
<td>0</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.42</td>
<td>$15.00</td>
<td>$221.0K</td>
<td align="right">62</td>
<td>2.0K</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$4.55</td>
<td>$4.4</td>
<td>$4.42</td>
<td>$15.00</td>
<td>$212.6K</td>
<td align="right">62</td>
<td>1.2K</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$10.00</td>
<td>$160.0K</td>
<td align="right">426</td>
<td>540</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$4.6</td>
<td>$4.5</td>
<td>$4.55</td>
<td>$15.00</td>
<td>$113.7K</td>
<td align="right">62</td>
<td>750</td>
</tr>
</tbody>
</table>

<h3>About XPeng</h3>
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 141,000 EVs in 2023, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
<h3>Present Market Standing of XPeng</h3>
<ul>
<li>Trading volume stands at 7,724,989, with XPEV's price down by -2.77%, positioned at $12.29.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 117 days.</li>
</ul>
<h3>Expert Opinions on XPeng</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $13.85.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein persists with their Market Perform rating on XPeng, maintaining a target price of $14. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on XPeng, maintaining a target price of $13. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest XPeng options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

XPEV

XPeng Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bearish stance on TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TGTX, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for TG Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 62%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $34,000, and 7, calls, for a total amount of $308,212.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $35.0 for TG Therapeutics over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for TG Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of TG Therapeutics's whale trades within a strike price range from $20.0 to $35.0 in the last 30 days. 
<h3>TG Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732209527_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.7</td>
<td>$4.6</td>
<td>$4.65</td>
<td>$33.00</td>
<td>$57.7K</td>
<td>634</td>
<td align="right">216</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$3.9</td>
<td>$1.4</td>
<td>$2.85</td>
<td>$30.00</td>
<td>$57.0K</td>
<td>785</td>
<td align="right">200</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.8</td>
<td>$4.7</td>
<td>$4.69</td>
<td>$33.00</td>
<td>$51.6K</td>
<td>634</td>
<td align="right">327</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.4</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$30.00</td>
<td>$47.6K</td>
<td>3.3K</td>
<td align="right">46</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.0</td>
<td>$13.7</td>
<td>$14.0</td>
<td>$20.00</td>
<td>$42.0K</td>
<td>4.3K</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About TG Therapeutics</h3>
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
<h3>Current Position of TG Therapeutics</h3>
<ul>
<li>Trading volume stands at 2,197,517, with TGTX's price up by 13.42%, positioned at $35.33.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 97 days.</li>
</ul>
<h3>Expert Opinions on TG Therapeutics</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $42.333333333333336.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen downgraded its action to Buy with a price target of $50. 
&#x2A; An analyst from HC Wainwright &amp; Co. has decided to maintain their Buy rating on TG Therapeutics, which currently sits at a price target of $55. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Neutral rating on TG Therapeutics with a target price of $22. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for TG Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

TGTX

A Closer Look at TG Therapeutics's Options Market Dynamics

Deep-pocketed investors have adopted a bullish approach towards IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in IBM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for IBM. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 33% bearish. Among these notable options, 3 are puts, totaling $297,245, and 12 are calls, amounting to $890,977.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $290.0 for IBM, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of IBM stands at 3537.12, with a total volume reaching 4,514.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in IBM, situated within the strike price corridor from $200.0 to $290.0, throughout the last 30 days.
<h3>IBM Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732209522_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.55</td>
<td>$5.45</td>
<td>$5.55</td>
<td>$220.00</td>
<td>$265.2K</td>
<td>6.2K</td>
<td align="right">998</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.7</td>
<td>$5.65</td>
<td>$5.7</td>
<td>$220.00</td>
<td>$243.3K</td>
<td>6.2K</td>
<td align="right">349</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.65</td>
<td>$15.5</td>
<td>$15.65</td>
<td>$225.00</td>
<td>$148.6K</td>
<td>203</td>
<td align="right">8</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.75</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$230.00</td>
<td>$113.0K</td>
<td>380</td>
<td align="right">100</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.15</td>
<td>$1.11</td>
<td>$1.15</td>
<td>$290.00</td>
<td>$63.1K</td>
<td>1.6K</td>
<td align="right">550</td>
</tr>
</tbody>
</table>

<h3>About IBM</h3>
IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 350,000 people. The company has a robust roster of 80,000 business partners to service 5,200 clients, which includes 95% of all Fortune 500. While IBM is a B2B company, IBM's outward impact is substantial. For example, IBM manages 90% of all credit card transactions globally and is responsible for 50% of all wireless connections in the world.
Having examined the options trading patterns of IBM, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is IBM Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,687,689, with IBM's price up by 2.88%, positioned at $220.77.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>Expert Opinions on IBM</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $239.33333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $250. 
&#x2A; An analyst from BMO Capital has decided to maintain their Market Perform rating on IBM, which currently sits at a price target of $260. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on IBM, maintaining a target price of $208. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for IBM, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on IBM: Analyzing the Surge in Options Activity

Guggenheim analyst Ali Faghri maintains Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) with a Buy and raises the price target from $380 to $418.

Guggenheim Maintains Buy on Lithia Motors, Raises Price Target to $418

Global

Russia's Putin Says After Long-Range Strikes From Ukraine Regional Conflict Gained Elements Of Global One; Enemy Didn't Achieve Its Goals; Such Actions Won't Influence Situation In Ukraine; The Attacks On Russia With Western Weapons Will Not Change The Outcome Of The Special Operation; Russia Fired New Medium Range Ballistic Missile

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

Cullinan Therapeutics (CGEM) announced the upcoming presentation of preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at Am...

Cullinan Therapeutics to present preclinical data for CLN-978

TD Cowen analyst Marc Frahm has maintained their bullish stance on CGEM stock, giving a Buy rating on October 29. Marc Frahm has given his Buy rati...

Cullinan Management's Promising Pipeline and Strategic Advancements Justify Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cullinan Management (CGEM – Research Report), Intell...

Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Intellia Therapeutics (NTLA)

Cullinan Therapeutics (CGEM) will present new preclinical data for CLN-978, its novel CD19xCD3 T cell engager. These data and the study schema for ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of $34.00. Sou...

Cullinan Therapeutics: Promising Developments and Strategic Growth in Autoimmune Therapies

Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target of ...

Promising Developments in Cullinan Management's CLN-978 TCE for Autoimmune Diseases Drive Buy Rating

Cullinan Management (CGEM – Research Report) received a Buy rating and a $36.00 price target from Wedbush analyst Robert Driscoll today. The compan...

Cullinan Management (CGEM) Has a New Rating from Wedbush

Cullinan Management, Inc. ( ($CGEM) ) has released its Q3 earnings. Here is a breakdown of the information Cullinan Management, Inc. presented to i...

Cullinan Therapeutics Announces Q3 2024 Progress and Outlook

BPMC

CATX

CGON

HAFC

IDYA

IMCR

IOVA

JANX

KURA

MRUS

NKTX

NRIX

NTLA

NUVL

SIRI

SNDX

Earnings

Press Releases

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Comments

Cullinan Therapeutics

Cullinan Therapeutics (CGEM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga